METHOD FOR PREDICTING FIVE-YEAR NONMETASTATIC SURVIVAL IN BREAST CANCER PATIENTS BASED ON THE EXPRESSION OF THE YKL-39 AND CCL18 PROTEIN GENES Russian patent published in 2018 - IPC G01N33/574 C12Q1/68 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and is designed to predict five-year non-metastatic survival in patients with breast cancer. Molecular genetic study of biopsy specimens of tumor tissue is carried out, followed by isolation of RNA and determination of the level of expression of YKL-39 and CCL18 genes with the help of a quantitative polymerase chain reaction in real time. As a calibrator, normal breast tissue is used, in which the expression level of the YKL-39 and CCL18 genes is 1UU. With expression level of YKL-39 and CCL18 greater than 1UU with a combination of YKL-39⁺CCL18⁺ genes predict 100 % five-year non-metastatic survival. In case of combinations YKL-39⁺CCL18⁻, YKL-39⁻CCL18⁺, YKL-39⁻CCL18⁻ predict a risk of hematogenous metastases in 85 %, 71 % and 69 % of cases, respectively.

EFFECT: invention provides expansion of the field of application of the method by using an additional marker.

1 cl, 1 dwg, 4 ex